SCHEMBL14725588

SCHEMBL14725588

CCC(C)(CC(C)(CC(C)(C)C(=O)NCCCCCC(=O)NC)C(=O)NCCCN=[N+]=[N-])C(=O)NCC(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18752084 0.90 — —
SCHEMBL14725590 0.77 — —
SCHEMBL13403089 0.73 RIPK1 (0.33) —
SCHEMBL12603383 0.72 PAOX (0.31) —
SCHEMBL26483840 0.72 EPHX1 (0.34) —
SCHEMBL26483870 0.72 EPHX1 (0.34) —
SCHEMBL13253170 0.71 — —
SCHEMBL12603384 0.71 — —
SCHEMBL14725591 0.71 MAPT (0.32) —
SCHEMBL26483875 0.69 EPHX1 (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107513-A1 MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) BANK OF AMERICA, N.A. 2017-04-20 — — US disclosed
US-9198972-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) ALNYLAM PHARMACEUTICALS, INC. (US) 2015-12-01 — — US disclosed
US-20130053334-A1 MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) ALNYLAM PHARMACEUTICALS, INC. (US) 2013-02-28 — — US disclosed
Send feedback